Evidence map›Paper›PMID 42271289›Full record

ArticleBMC cancer2026

Clinical benefit of various HER2-directed regimens in gastrointestinal malignancies: a retrospective cohort study.

Vishesh Khanna, Swetha Vadde, A Solomon Henry, Tyler P Johnson, Shagufta Shaheen, Gregory M Heestand, Thomas Holden, Curtis R Chong, Lipika Goyal, George A Fisher and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vishesh KhannaDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Swetha VaddeDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
A Solomon HenryResearch Informatics Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Tyler P JohnsonDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Shagufta ShaheenDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Gregory M HeestandDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Thomas HoldenDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Curtis R ChongDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Lipika GoyalDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
George A FisherDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Christopher T ChenDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States. ctjchen@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple drugs targeting the human epidermal growth factor receptor-2 (HER2) have shown clinical activity in gastrointestinal (GI) cancers. How to best integrate these various options in clinical practice alongside conventional therapy, however, is unclear.

methodsWe assessed the clinical outcomes of 103 patients with advanced HER2-altered GI malignancies who received ≥ 1 line of anti-HER2 therapy at our institution between 2010 and 2023.

resultsNext-generation sequencing (NGS) detected an ERBB2 amplification in 66% (27/41) of tumors that were HER2 + by IHC/ISH. Conversely, all patients with ERBB2 amplification were HER2 + by IHC. In the second-line and beyond, trastuzumab plus pertuzumab had the longest median time to treatment discontinuation (7.9 months), followed by trastuzumab deruxtecan (5.0 months). Among 25 patients who received ≥ 2 anti-HER2 agents, 24% had more durable clinical benefit to their second-line HER2 therapy compared to their first, as measured by the growth modulation index.

conclusionsMultimodal HER2 testing is needed to accurately identify candidates for HER2-targeted treatment, as NGS alone misses a significant proportion of cases. Patients who develop resistance to one anti-HER2 agent may still achieve benefit from subsequent HER2-directed regimens. Early and serial treatment with HER2-directed agents should be considered for patients with HER2 + GI cancers.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesGastrointestinal NeoplasmsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCamptothecinFemaleGene AmplificationHigh-Throughput Nucleotide SequencingHumansImmunoconjugatesMiddle AgedRetrospective StudiesTrastuzumabAntibodies, Monoclonal, HumanizedCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatespertuzumabTrastuzumabtrastuzumab deruxtecanAnti-HER2 therapyGastrointestinal malignanciesHER2Treatment sequencing

Identifiers

PMID42271289
PMCPMC13474698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.